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Bipolar Disorder: A Retrospective Chart Review of Efficacy and Tolerability
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Division of Child and Adolescent Psychiatry, Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University 
College of Medicine, Seoul, Korea
Objective: This study compared the efficacy and tolerability of aripiprazole with that of other atypical antipsychotics by examining 
patients with pediatric bipolar disorder (PBD) at a child and adolescent psychiatric clinic in a university hospital in Korea.
Methods: We reviewed the medical records of 127 pediatric patients with bipolar disorder aged 4-18 years treated at Department 
of Child and Adolescent Psychiatric, Yonsei University Severance Hospital between January 2010 and October 2011 to collect 
demographic and clinical data. Using the Clinical Global Impression (CGI) scales, we evaluated levels of severity of and improve-
ments in symptoms at the first, second, third, fourth, and fifth hospital visits.
Results: The mean age of patients was 12.29±3.47 years. The sample included 91 (71.7%) male and 36 (28.3%) female patients. 
Aripiprazole was prescribed to 62 (48.8%) patients, risperidone to 52 (40.9%), quetiapine to 11 (8.7%), and paliperidone to two 
(1.6%). Patients treated with aripiprazole had lower CGI-Severity (CGI-S) scores than did patients treated with other atypical 
antipsychotics at the second and third visits. The CGI-Improvement (CGI-I) scores of patients treated with aripiprazole were 
lower at the second visit. Treatment with atypical antipsychotics was well tolerated, and no serious or fatal side effects were 
observed.
Conclusion: The present retrospective chart review suggests that atypical antipsychotics may be effective and safe for the 
treatment of patients with PBD. In particular, treatment with aripiprazole may be more effective than treatment with other atypical 
antipsychotics in the early phase. These results should be verified in future multi-center controlled studies.
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INTRODUCTION
Pediatric bipolar disorder (PBD) is characterized by a 
chronic and serious progression1) and a poor prognosis.2) 
Additionally, it has been reported that 50-66% of cases of 
adult bipolar disorder begin in childhood and adolescen-
ce.3) PBD was previously considered to be rare. However, 
since the mood-related and behavioral features of PBD 
have come to be recognized as different from those of bi-
polar disorder in adults and as the importance of in-
dividual symptoms has been emphasized, PBD is now 
thought to be more common. Children and adolescents ex-
perience faster changes in mood and behavior than do 
adults, and they sometimes also suffer from conditions 
such as attention deficit hyperactivity disorder (ADHD). 
Moreover, patients with childhood/adolescent-onset bipo-
lar disorder have more manic and depressive episodes 
than do those with adult-onset bipolar disorder.4) Psycho-
pharmacotherapy is essential in the treatment of PBD, and 
mood stabilizers and atypical antipsychotics are currently 
the most frequently considered primary drugs for this 
purpose.5) The combined administration of multiple 
agents has also been reported to be effective for bipolar 
disorder and concomitant conditions.6) Additionally, ad-
ministration of either lithium or valproic acid in actual 
clinical cases has not been sufficiently effective for 
long-term treatment.7) However, long-term use of com-
bined agents presents a safety problem in children and 
adolescents.8)
Among the various agents used for adult patients with 
bipolar disorder, atypical antipsychotics have been proven 
effective,9) and exclusive use of these agents in children 
and adolescents has also been reported to be effective.10) 
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Retrospective studies on the efficacy and safety of atyp-
ical antipsychotic agents, such as aripiprazole, for patients 
with PBD have been conducted in the US.11,12) Double- 
blind placebo-control studies on long-term maintenance 
treatment with aripiprazole in children and adolescents 
are also currently in process.13)
One of the atypical antipsychotics, aripiprazole, acts as 
a partial agonist at the dopaminergic D2 receptor and sero-
tonin HT1A receptor and as an antagonist at the serotonin 
5HT2A receptor. Because of these characteristics, aripi-
prazole has been known to have mild side effects and to be 
safe for pediatric patients suffering from such symptoms 
as tics.14) In particular, the low sedating effect and low 
weight gain associated with this drug may make it easier 
for pediatric patients to function at school.
Thus, it is necessary to study the prescribing pattern, ef-
ficacy, and safety of aripiprazole and other atypical anti-
psychotics for pediatric patients. Indeed, extant research 
on the efficacy and safety of diverse agents for the treat-
ment of PBD is not adequate. As far as we know, few stud-
ies on the patterns of administration to patients with PBD 
have been conducted in Korea, and no known study has 
compared the efficacy of each agent in Korean popula-
tions. The purpose of this study was to compare the effi-
cacy and tolerability of aripiprazole with those of other 
atypical antipsychotics by investigating patients with 
PBD at a child and adolescent psychiatric clinic in a uni-
versity hospital in Korea.
METHODS  
Patients aged 4-18 years who received outpatient treat-
ment at Department of Child and Adolescent Psychiatry, 
Yonsei University Severance Hospital (Seoul, Korea) be-
tween January 2010 and October 2011 were selected for 
inclusion in the present study. Chart reviews were con-
ducted for the 183 patients who were screened through a 
search for bipolar I disorder, bipolar II disorder, bipolar 
disorder, and bipolar affective disorder. Of these 183 pa-
tients, those whose main reason for treatment was another 
diagnosis, such as tic disorder or ADHD, were excluded, 
as were those who visited the clinic only once or did not 
take mediation. After exclusion, 127 patients who were 
diagnosed by child psychiatrists with bipolar I disorder, 
bipolar II disorder, or bipolar disorder not otherwise speci-
fied according Diagnostic and Statistical Manual of 
Mental Disorders (DSM)-IV criteria were finally selected 
for participation in the present study. We also gathered 
demographic and clinical data including sex, age, in-
telligence quotient (IQ), diagnosis, illness duration, con-
comitant diseases, types and dosages of atypical anti-
psychotics administered, treatment period, concomitant 
psychiatric illnesses, other agents administered, and side 
effects. Most patients with ADHD-like symptoms were 
assessed before and after treatment using the ADHD 
Rating Scale (ARS) to evaluate the severity of their 
symptoms.15)
Severity of and improvement in symptoms were eval-
uated prior to administration of atypical antipsychotics 
and at every visit using the Clinical Global Impression- 
Severity (CGI-S: 1=not ill, 7=extremely ill) and the CGI- 
Improvement (CGI-I: 1=very much improved, 7=very 
much worse) scales.16) The CGI scores of patients receiv-
ing aripiprazole were compared with those receiving other 
atypical antipsychotics (risperidone, quetiapine, paliper-
idone) at the first, second, third, fourth, and fifth hospital 
visits. The second visit followed the first by about 2 
weeks, the third visit followed the second by about 1 
month, the fourth visit followed the third by about 2 
months, and the fifth visit followed the fourth by about 4 
months. Data from patients who visited more than 1 week 
before or after the scheduled visit day were excluded from 
the analyses of that data point. We thereby excluded the 
data from three patients from analyses of the second visit, 
data from 14 patients from analyses of the third visit, data 
from 25 patients from analyses of the fourth visit, and data 
from 53 patients from analyses of the fifth visit. Owing to 
these missing data, we compared CGI scores using a linear 
mixed model.
RESULTS
The mean age of the 127 subjects with bipolar disorder 
was 12.29±3.47 (ranging from 4 to 18 years of age); 53 
subjects were younger than 12 years, and 74 were 12 years 
or older. The sample included 91 (71.7%) male and 36 
(28.3%) female participants. The mean age of the male pa-
tients was 11.64±3.38 years, which was significantly 
younger than that of the female patients, 13.94±3.39 years 
(p＜0.01). The male and female patient groups did not dif-
fer in terms of duration of illness or IQ. Patients treated 
with aripiprazole did not differ significantly from those 
treated with other agents except that those receiving aripi-
prazole were significantly older than those receiving other 
medications (Table 1).
At the time of starting treatment, the mean illness dura-
tion of patients was 24.80±17.88 months. The mean over-
all IQ was 91.75±20.88; the mean verbal IQ was 95.14± 
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Table 1. Clinical characteristics of the subjects with aripiprazole versus with others
Characteristic Total (n=127) Aripiprazole (n=62) Others (n=65) p value
Age (year) 12.29±3.47 13.16±2.80 11.46±3.95 0.001*,†
Gender (male/female)
Duration (month)
91/36 41/21 50/15 0.177‡
  Illness 24.80±17.88 26.23±20.08 23.43±15.68 0.114†
  Medication 7.84±5.27 8.24±5.90 7.46±4.61 0.410†
  VIQ 95.14±21.49 99.07±19.01 91.74±23.26 0.198†
  PIQ 88.89±18.93 91.46±18.09 86.66±19.70 0.891†
  TIQ 91.75±20.88 95.14±18.52 88.62±22.76 0.300†
Values are presented as mean±standard deviation, or number.
*p＜0.01. †student t-test, ‡chi-square test. 
IQ, intelligence quotient; VIQ, verbal IQ; PIQ, performance IQ; TIQ, total IQ.
Fig. 1. Type of atypical antipsychotics used for pediatric bipolar 
disorder.
Table 2. Mean dose and medication duration of atypical antipsychotics
Aripiprazole Risperidone Quetiapine Paliperidone
Mean dose (mg) 9.58±5.38 1.46±1.08 207.46±200.53 4.50±2.12
Medication duration (month) 8.24±5.90 7.50±4.12 7.27±6.86 7.50±4.95
Values are presented as mean±standard deviation.
Table 3. Comorbidity of the bipolar subjects
Comorbidity Data
None 43 (33.9)
ADHD 50 (39.4)
Tic related disorders 17 (13.4)
Conduct disorder and ODD 5 (3.9)
Autism spectrum disorder 12 (9.4)
Values are presented as number (%).
ADHD, attention deficit hyperactivity disorder; ODD, oppositional 
defiant disorder.  
21.49, and the mean performance IQ was 88.89±18.93.
The mean drug administration period, defined as the pe-
riod from when the primary agent was selected through 
the time the drug was continuously administered, was 
7.8±5.3 months. Aripiprazole was administered to 62 
(48.8%) patients as the major agent, risperidone to 52 
(40.9%), quetiapine to 11 (8.7%), and paliperidone to two 
(1.6%) (Fig. 1). Of the 127 patients, 10 received two atyp-
ical antipsychotics simultaneously, but identification of 
the major agent was not difficult (e.g., quetiapine, at 700 
mg, was the major agent and risperidone, at 1 mg, was also 
prescribed). One patient was treated with 20 mg of aripi-
prazole and 4 mg of risperidone at the last visit, but this in-
dividual had been started at 20 mg aripiprazole and had 
slowly added risperidone; therefore, aripiprazole was 
identified as the major agent. The mean dose and medi-
cation duration of aripiprazole were 9.58±5.38 mg and 
8.24±5.90 months, respectively. In terms of chlorproma-
zine-equivalent doses, aripiprazole was administered at 
higher doses than were other agents, and aripiprazole was 
administered for about a month longer than were other 
agents (Table 2).
Forty-three (33.9%) patients did not have a comorbid 
disorder, whereas 84 (66.1%) did. Fifty (39.4%) patients 
also met criteria for ADHD, and 17 (13.4%) had tic-re-
lated disorders. Five (3.9%) patients had conduct dis-
orders or oppositional defiant disorders. Additionally, 12 
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Fig. 2. (A) Effects on the attention deficit hyperactivity disorder 
(ADHD) rating scale scores of boys and girls by treatment. (B) 
Effects on ADHD rating scale scores of ADHD and non-ADHD by 
treatment. (C) Effects on ADHD rating scale scores of groups 
with ADHD medications and groups without ADHD medications 
by treatment. 
ARS, total score of ADHD rating scale; ARS_T, total score of 
ADHD rating scale after treatment. 
By paired t-test. (t=13.86, df=69, p＜0.001).
Table 4. Concomitant medication of the bipolar subjects
Concomitant medication Data
Mood stabilizers 20 (15.7)
Methylphenidate 34 (26.8)
Atomoxetine 12 (9.4)
Antidepressants 27 (21.3)
Values are presented as number (%).
(9.4%) patients were diagnosed with autism spectrum dis-
orders (Table 3).
Mood stabilizers such as valproic acid were addition-
ally administered to 20 (15.7%) patients, methylphenidate 
to 34 (26.8%), atomoxetine to 12 (9.4%), and anti-
depressants to 27 (21.3%) (Table 4).
The ARS was administered to 70 patients before and af-
ter treatment; the mean ARS score before treatment was 
24.9±11.4, and the mean ARS score after treatment was 
13.1±5.5 (t=13.86, df=69, p＜0.001). The scores of 55 
male patients changed from 25.0±9.5 to 13.4±4.7, and 
those of 15 female patients changed from 24.5±17.3 to 
12.07±8.0 (Fig. 2A). Before treatment, the mean ARS 
score of 39 patients with ADHD was 28.59±9.25, which 
was significantly higher than that of patients without 
ADHD, 20.26±12.42. After treatment, the mean ARS 
score of patients with ADHD was 14.62±4.03, and that of 
patients without ADHD was 11.16±6.57, reflecting that 
these scores were still significantly higher in those with 
ADHD (Fig. 2B). Before treatment, the mean ARS score 
of 37 patients receiving methylphenidate or atomoxetine 
was 27.54±10.65; their mean ARS score after treatment 
was 14.05±5.10. The mean ARS score of 33 patients who 
were not receiving ADHD medications changed from 
21.94±11.79 to 12.00±5.88 (Fig. 2C).
Figs 4, 5 show comparisons between patients ad-
ministered aripiprazole and those administered other 
atypical antipsychotics in terms of CGI-S and CGI-I 
scores at the first, second, third, fourth, and fifth hospital 
visits. Although many subjects participated in the entire 
testing process, three patients missed the second visit 
(about 2 weeks after the first visit), 14 missed the third vis-
it (about 1 month after the second visit), 25 missed the 
fourth visit (about 2 months after the third visit), and 53 
missed the fifth visit (about 4 months after the third visit). 
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Fig. 4. Comparison of Clinical Global Impression-Improvement 
(CGI-I) score between aripiprazole and other atypical 
antipsychotics by visit. 
By linear mixed model, post-hoc analysis; *p＜0.05.
Fig. 3. Comparison of Clinical  Global Impression-Severity (CGI-S) 
score between aripiprazole and other atypical antipsychotics by visit. 
By linear mixed model, post-hoc analysis; *p＜0.05, †p＜0.005.
Table 5. Side effects of atypical antipsychotics
Side effect Aripiprazole Risperidone Quetiapine Paliperidone
None 37 (59.7) 13 (25.0) 1 (9.1) 1 (50.0)
Rigidity 13 (21.0) 4 (7.7) 1 (9.1) 0 (0)
Akathisia 5 (8.1) 3 (5.8) 1 (9.1) 0 (0)
Sedation 1 (1.6) 2 (3.8) 1 (9.1) 0 (0)
Appetite increase 4 (6.5) 24 (46.2) 7 (63.6) 0 (0)
Others (nausea, dizziness) 2 (3.2) 6 (11.5) 0 (0) 1 (50.0)
Values are presented as number (%).
The mean period of administering aripiprazole (8.2±5.9 
months) was longer than that of administering other atyp-
ical antipsychotics (7.5±4.6 months), but this difference 
was not significant (p=0.410).
The CGI-S scores of the two groups did not differ at the 
first hospital visit, but those receiving aripiprazole scored 
lower on the CGI-S than did those receiving atypical anti-
psychotics at the second and third visits. No between- 
group differences in CGI-S scores were observed at the 
fourth or fifth hospital visit. Although the differences did 
not reach significance, CGI-S scores increased slightly in 
the group treated with other atypical antipsychotics, and 
they were higher in this group than in the group treated 
with aripiprazole at the fifth visit (Fig. 3). Scores on the 
CGI-I were compared at the second visit and at every sub-
sequent visit. The CGI-I scores of those receiving aripi-
prazole were significantly lower than those receiving oth-
er medications at the second visit, indicating more im-
provement in the former than in the latter. No significant 
differences between the groups were observed after the 
second visit (Fig. 4). 
Thirty-seven (59.7%) of 62 patients administered aripi-
prazole reported no side effects, whereas 13 (21.0%) re-
ported rigidity, five (8.1%) reported akathisia, one (1.6%) 
reported sedation, and four (6.5%) reported increased 
appetite. Thirteen (25.0%) of 52 patients administered ris-
peridone reported no side effects, whereas four (7.7%) re-
ported rigidity, three (5.8%) reported akathisia, two 
(3.8%) reported sedation, and 24 (46.2%) reported in-
creased appetite. One (9.1%) of 12 patients administered 
quetiapine reported no side effects, whereas one (9.1%) 
reported rigidity, one (9.1%) reported akathisia, one 
(9.1%) reported sedation, and seven (63.6%) reported in-
creased appetite (Table 5).
DISCUSSION
This retrospective chart review of patients with PBD 
found that atypical antipsychotics, such as aripiprazole, 
reduced the severity of and contributed to improvements 
in clinical symptoms. At least 40% of patients reported no 
side effects associated with atypical antipsychotics, and 
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the remaining patients found the side effects they experi-
enced to be comparatively tolerable. Additionally, with 
the exception of increased appetite, no significant differ-
ences were found among the agents used in terms of side 
effects.
The age and sex distributions of the patients included in 
this study were similar to those in previous studies.17-19) 
The number of male patients treated for PBD was more 
than double that of female patients, and the mean age of 
male patients was younger than that of female patients.20) 
These results are consistent with those of previous studies 
reporting that bipolar disorder develops earlier in males 
than in females. Other than age, no significant differences 
were found between male and female patients.
In the present study, 66.1% of all patients had con-
comitant conditions such as ADHD or tic-related 
disorders. This figure is lower than the 90% or more of pa-
tients who had ADHD in previous studies, and the preva-
lence of comorbid disruptive disorder was also lower than 
that in the prior research.21,22) The prevalence of autism 
spectrum disorders was 9.4%, which is also lower than the 
15% reported in previous studies.23) As the medications 
were administered for a mean of only 7.8 months in the 
present study, it is possible that insufficient consideration 
was given to the identification of concomitant disorders in 
this outpatient population. Indeed, symptoms that are 
common to mania, ADHD, and disruptive disorders may 
have led to differences among studies in the diagnosis of 
comorbid conditions. Additionally, we devoted insuffi-
cient attention to patients with two or more concomitant 
disorders. Originally, comorbid ADHD was identified in 
50 patients; however, 70 patients completed the ARS be-
fore and after treatment with atypical antipsychotics, and 
the scores of these patients decreased by nearly 10 points, 
which indicates improvement. In particular, similar to pa-
tients treated with methylphenidate or atomoxetine, pa-
tients who were not treated with ADHD medications also 
showed substantial improvements in their ADHD symp-
toms. Even though we cannot determine whether their im-
provement was due to the atypical antipsychotics or to 
other medications, such as mood stabilizers, the atypical 
antipsychotics may have had some influence on the 
ADHD symptoms. In fact, psychostimulants are com-
monly used to treat ADHD, which is commonly found in 
patients with PBD and which may cause exacerbation of 
manic symptoms. For this reason, research has examined 
the additional use of atypical antipsychotics to improve 
manic symptoms and ADHD.24) In the present study, 46 
patients received methylphenidate and atomoxetine in ad-
dition to atypical antipsychotics. Although some patients 
did not complete the ARS, improvements in the symptoms 
of both bipolar disorder and ADHD were confirmed, and 
this result is consistent with those of previous studies.
In the present study, use of aripiprazole and other atyp-
ical antipsychotics was shown to improve CGI-I and 
CGI-S scores. The CGI-S scores of the group treated with 
aripiprazole were lower than were those of the group treat-
ed with other agents at the second and third hospital visits, 
and the CGI-I scores of the aripiprazole group were also 
lower than were those of the other group at the second 
visit. This implies that the response to aripiprazole at the 
early stage of administration is better than that to other 
agents. Therefore, use of aripiprazole for early acute 
symptoms may be more effective than use of other agents. 
Additionally, although the difference was not statistically 
significant, at the fifth visit, the CGI-I and CGI-S scores of 
patients who received aripiprazole were lower were than 
those of patients who received agents other than aripi-
prazole. In view of the increase in the CGI-S scores be-
tween the fourth and fifth visits shown by patients receiv-
ing other atypical antipsychotics, it is possible that the 
long-term use of aripiprazole for maintenance treatment 
may also result in better outcomes. It should be noted, 
however, that many patients missed their fifth hospital vis-
it, which may render these data invalid.
More than 40% of patients who were administered ari-
piprazole, risperidone, quetiapine, and paliperidone in the 
present study did not experience side effects, and abso-
lutely no serious or fatal side effect was observed. As side 
effects such as rigidity, sedation, and akathisia were ob-
served in less than 25% of subjects, use of atypical anti-
psychotics for patients with PBD is considered to be safe. 
Aripiprazole was expected to show fewer side effects 
compared with other agents, but no significant differences 
were found with regard to extrapyramidal symptoms and 
sedation. This may be due to an insufficient number of 
subjects and differences in dosages. The results show that 
aripiprazole and other agents had similar levels of side ef-
fects, but more favorable effects were obtained from aripi-
prazole compared with other agents. Moreover, aripipra-
zole was associated with lower rates of increased appetite 
than were other atypical antipsychotics. This strength of 
aripiprazole may enhance the compliance of pediatric 
patients.
This study had the following limitations. First, it used a 
retrospective design that relied on chart reviews. Thus, no 
placebo-control group was included, and the review proc-
ess may have been biased because assessments of diag-
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noses, treatment effects, and side effects were made retro-
spectively based on charts. The reliance on chart reviews 
also precluded control of a sufficient number of pop-
ulation parameters, medication doses, concomitant medi-
cations, and comorbid disorders. Second, the intervals be-
tween hospital visits were not exactly consistent among 
patients, and this may have adversely affected our assess-
ment of treatment effects. Third, the present study drew on 
patients at a single institution, and the number of subjects 
is too small to permit generalizations based on study 
results. Finally, insufficient consideration was given to 
concomitant conditions that are common among patients 
with PBD (e.g., anxiety disorders) during the review proc-
ess, and side effects such as weight gain and hyper-
prolactinemia were also not completely assessed.
Despite these limitations, the present study used a natu-
ralistic chart-review design that reflected actual prescrib-
ing patterns and yielded data on treatment effects and side 
effects from a clinical setting. Thus, it provides practical 
information that can be used for clinical purposes. Indeed, 
the present study provides useful information about PBD 
in patients in Korea. First, although the effects of agents 
administered in addition to antipsychotics, such as mood 
stabilizers, cannot be excluded, the use of atypical anti-
psychotics in Korean patients with PBD was confirmed as 
effective for improving the symptoms of bipolar disorder 
without leading to significant side effects. In particular, 
the early treatment effects and long-term tolerability of 
aripiprazole were found to be excellent compared with 
those of other atypical antipsychotics. The superior treat-
ment effects of aripiprazole,25) which was also associated 
with comparatively mild side effects, may enhance the 
treatment compliance of pediatric patients and their 
guardians. However, these results must be confirmed in 
the future through multi-center, double-blind, place-
bo-control studies.
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